Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors

Patients with autoimmune rheumatic diseases (ARD) have an increased risk for tuberculosis (TB). The use of tumor necrosis factor inhibitors (TNFi) and glucocorticoids in these patients has been associated with an increased prevalence of latent TB reactivation. Over the last few years, several biolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Evangelatos, Gerasimos, Koulouri, Vasiliki, Iliopoulos, Alexios, Fragoulis, George E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
When Rheumatology and Infectious Disease Come Together
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309385/
https://www.ncbi.nlm.nih.gov/pubmed/32612710
http://dx.doi.org/10.1177/1759720X20930116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309385/
https://www.ncbi.nlm.nih.gov/pubmed/32612710
http://dx.doi.org/10.1177/1759720X20930116

Ejemplares similares